Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

HuiSheng Biology

Request full access

Is China's only pharmaceutical company with products that target diabetes and all its complications

ChinaFounded 2014Biotech & Life Sciences

About HuiSheng Biology

HuiSheng Biopharmaceutical Co., Ltd. operates as a biopharmaceutical enterprise focused on the treatment of diabetes and its associated complications. Established in 2019 in Jilin, China, the company is a subsidiary of the Sihuan Pharmaceutical Holdings Group. The firm's activities encompass the development and manufacturing of both biological and chemical drug products.

The company is led by CEO Haiyan Cao, who brings over two decades of experience in biopharmaceutical product development, clinical guidance, and project management to the role. HuiSheng Bio-pharmaceutical has established a significant presence in Jilin, with additional branches in Changchun and Beijing. As of 2022, the company's infrastructure supports an annual production capacity of 50 million units of insulin and it holds 10 patents. Its product pipeline is extensive, with more than 40 products addressing diabetes and its complications. These products fall into several categories, including insulin and its analogs, GLP-1 analogs, biguanides, DPP-4 inhibitors, SGLT-2 inhibitors, and glinides.

HuiSheng Biopharmaceutical's business model is geared towards serving the needs of patients with diabetes by developing a comprehensive range of therapeutic options. The company has secured funding from investors such as Grand Flight Investment, China Life Capital, and TONGHE DINGTAI INVESTMENT MANAGEMENT LIMITED to support its research and development efforts. The company has received venture capital backing, completing a Series A1 funding round in January 2023, which raised $83.2 million, and a Series A round in June 2022. This financial support enables the company to advance its diverse product pipelines and strengthen its position in the diabetes care market.

The company's product portfolio includes items like Prourogliflozin Tablets, Degludec Insulin, Degludec & Aspart Insulin, and Aspart Insulin, alongside various active pharmaceutical ingredients (APIs) and intermediates. By focusing on a specialized area of medicine and developing a wide array of products, HuiSheng Biopharmaceutical aims to provide comprehensive solutions for individuals managing diabetes. The company's structure and strategic investments reflect a commitment to addressing the complexities of diabetes treatment through a combination of biological and chemical pharmaceutical approaches.

Source: Dealroom company data

At a glance

Status
Operational
Employees
17
Open positions
None listed
Dealroom signal
36.0/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jan 2023 $80M $767M Baixing Bairong · Jilin Province Technology Investment Fund · JiLin Province Private Equity ↗
SERIES AOther financing Jun 2022 $69M $275M Grand Flight Investment · Ginko Ventures · China Life Private Equity Investment · Yuanyi Investment ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

HuiSheng Biology website traffic

Latest recorded traffic for HuiSheng Biology is 7.2K monthly website visits. HuiSheng Biology's team grew 0% over the past year.

Latest monthly visits7.2K 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

HuiSheng Biology in its local ecosystem

Live from Dealroom

The HuiSheng Biology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

  • Grand Flight Investment
  • Ginko Ventures
  • China Life Private Equity Investment
  • Yuanyi Investment
  • Baixing Bairong
  • Jilin Province Technology Investment Fund
  • JiLin Province Private Equity
Employees 17 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇳 China71.4%
🇭🇰 Hong Kong14.3%
🇸🇬 Singapore14.3%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about HuiSheng Biology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See HuiSheng Biology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.